miR-152在声门上型喉癌中的表达及临床病理关系  

Expression of miR-152 and its clinical pathological significance in supragalottic laryngeal carcinoma

作　　者：迟慧 宋岩[1] 那迪[2] 白伟良[1] CHI Hui SONG Yan NA Di BAI Wei-liang(Department of Otorhinolaryngology, Shengjing Hospital of China Medical University, Shenyang 110004, China the First Hospital of China Medical University, Shenyang 110001, China)

机构地区：[1]中国医科大学附属盛京医院 [2]中国医科大学附属第一医院

出　　处：《实用药物与临床》2017年第10期1135-1138,共4页Practical Pharmacy and Clinical Remedies

基　　金：辽宁省教育厅科学研究一般项目(L2015586);沈阳市科学计划项目资助(F13-220-9-21);辽宁省科学事业公益研究基金(2013001010);辽宁省自然科学基金(20170541043)

摘　　要：目的探讨并分析miR-152在声门上型喉癌组织中的表达情况,为进一步研究miR-152用于治疗靶向药物、评估预后提供参考依据。方法采用Real-time PCR法检测83例患有声门上型喉癌患者癌组织中miR-152的表达,并将miR-152的表达数据与临床病理数据进行对比分析。最后,通过MTT方法对比转染了miR-152模拟物组和阴性对照组的Hep-2细胞系受抑制情况。结果miR-152在声门上型喉癌组织中显著低表达(t=12.65,P<0.001),并且其低表达与声门上型喉癌的T分期(χ~2=26.88,P<0.001)和N分期(Z=-3.56,P<0.001)相关。miR-152可抑制Hep-2细胞增殖。结论miR-152可能作为声门上型喉癌预后的新靶点。Objective To discuss and analyze the expression of miR-152 in tissues of patients with supragalottic laryngeal carcinoma, and provide reference data for further study of the function of miR-152 in tumor target medicine and prediction of the prognosis of supragalottic laryngeal carcinoma. Methods The expression of miR-152 was detected in tissues of 83 patients with supragalottic laryngeal carcinoma by Real-time PCR, and the relationship between the expression of miR-152 and clinicopathological parameters was analyzed. The inhibition of the Hep-2 cells which was transfected with miR-152 mimics and transfected with mimics negative control by MTT was compared. Results miR-152 was significantly low-expressed in supragalottic laryngeal carcinoma（ t = 12. 65,P〈0. 001）. Moreover, low-expression of miR-152 was correlated with stage pT（ χ^2 = 26. 88,P〈0. 001） and stage pN（ Z =-3. 56,P〈0. 001） in supragalottic laryngeal carcinoma. MiR-152 could inhibit the cell proliferation in Hep-2 cells. Conclusion MiR-152 may act as a new tumor target to predict the prognosis of supragalottic laryngeal carcinoma.

关 键 词：声门上型喉癌 MiR-152 HEP-2细胞系 临床相关性 

分 类 号：R739.65[医药卫生—肿瘤]